rs113941206 - POU2AF3 - MIR4491
Magnitude 4.5 · 1 study on file
Reported associations
-
Genome-wide association study of liver enzyme elevation in an extended cohort of rheumatoid arthritis patients starting low-dose methotrexate. - Pharmacogenomics (2022) · Cavalli M, Eriksson N, Sundbaum JK, Wallenberg M, Kohnke H, Baecklund E, Hallberg P, Wadelius M · PubMed 36070248
A follow-up genome-wide association study (GWAS) in an extended cohort of rheumatoid arthritis (RA) patients starting low-dose methotrexate (MTX) treatment was performed to identify further genetic variants associated with alanine aminotransferase (ALT) elevation. A GWAS was performed on 346 RA patients. Two outcomes within the first 6 months of MTX treatment were assessed: ALT >1.5-times the upper level of normal (ULN) and maximum level of ALT. (rs72783407) was significantly associated with maximum level of ALT (p = 2.58 × 10 ) and (rs60427389) was tentatively associated with ALT >1.5 × ULN. Associations with SNPs in genes related to male fertility ( ) and inflammatory processes ( ) were identified.
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Drug interactions
-
methotrexate use in rheumatoid arthritis Moderate
This variant is associated with elevated alanine aminotransferase following methotrexate initiation in rheumatoid arthritis patients.
Discuss with your rheumatologist before starting methotrexate treatment.